Privately-held Italian drugmaker Fidia Farmaceutici plans to enter the Italian pediatric health care market with the acquisition of the HalyKoo Line developed by the Swiss-based company APR Applied Pharma Research specialized in the development of innovative and patent-protected products (prescription and over-the-counter), that are marketed worldwide
The HalyKoo products will be available in Italy starting next fall: this isthe first complete line of products offering, under only one unique brand, tailor-made therapeutic solutions, designed and developed for children’s health and wellbeing since newborns.
This partnership has enabled Fidia, which is specialized in the R&D and marketing of innovative products based on hyaluronic acid, to officially enter the pediatric market segment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze